Johnson & Johnson (JNJ) announced the launch of VARIPULSE Pro in Europe following CE Mark approval. The VARIPULSE Pro Platform features a new pulse sequence designed to streamline procedures and enhance workflow efficiency. The company will feature the VARIPULSE Pro Platform at the European Heart Rhythm Association annual meeting.
"The introduction of VARIPULSE Pro in Europe reflects our commitment to advancing our PFA platforms through continuous innovation, enhancing procedural experience while maintaining the consistency and precision physicians expect from the VARIPULSE Platform," said Michael Bodner, Company Group Chair, Electrophysiology & Neurovascular, MedTech, Johnson & Johnson.
In pre-market trading on NYSE, Johnson & Johnson shares are up 0.03 percent to $240.97.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.